Waters Corporation Names New President and CEO

Article

Udit Batra, PhD has been named Waters’ new president and CEO, effective September 1, 2020.

Waters Corporation announced on July 15, 2020 that Udit Batra, PhD has been named Waters’ new president and CEO, effective September 1, 2020. He will work alongside the company’s current president and CEO, Christopher O’Connell, who will remain in his role until Batra’s September start date.

Batra previously served as president and CEO of the global Consumer Health business of Merck KGaA in Darmstadt, Germany, and most recently held the role of CEO of Merck KGaA’s Life Science business, according to a company press release. There, he headed the business’ integration of Sigma-Aldrich, which resulted in the creation of MilliporeSigma, Merck KGaA’s United States and Canada identity.

“We are pleased to have identified such an accomplished and experienced candidate and are confident that Udit is the right leader to take Waters to the next level,” said Dr. Flemming Ornskov, chairman of the board at Waters, in the press release. “His focus on commercial execution and innovation, proven ability to build strong and collaborative cultures, and intense commitment to serving customers have translated into tangible results. Building on Waters’ strong foundation, we look forward to the company’s next phase of innovation and growth with Udit at the helm. We are grateful for the continued hard work and leadership of Chris and the entire Waters team to remain focused on our business, continue our progress, and ensure a seamless transition.”

“Throughout my career, I have focused on starting with listening and learning, embracing challenges, and working with talented people,” Batra added in the press release. “I join Waters with energy and a shared passion for technology development and serving our customers to drive value for shareholders while making the world a better place.”

Source: Waters

 

 

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content